Live Breaking News & Updates on Mark Plavsic

Stay updated with breaking news from Mark plavsic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and

Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical TrialPositive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023Preliminary Data from Phase 1 Trial in. ....

United States , Los Pinos , J Jill Hopkins , Mark Plavsic , Technology Officer , Suprachoroidal Administration , Novartis Company , Oncology Division , Company Phase , Aura Biosciences Inc , Exchange Commission , Exploratory Development At Novartis , Company Global Phase , Under Special Protocol Assessment , Compass Phase , Clinical Efficacy Updates , Early Stage Choroidal Melanoma , Ongoing Phase , Suprachoroidal Administration Presented , Bladder Cancer , First Patient Utilizing , Single Dose , Light Activation Demonstrated , Clinical Complete , Gross Proceeds , Underwritten Public ,

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Received FDA Agreement Under Special Protocol Assessment for the CoMpass Phase 3 Clinical Trial

Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing. ....

United States , Mark Plavsic , Los Pinos , J Jill Hopkins , Technology Officer , Company Phase , Exchange Commission , Exploratory Development At Novartis , Novartis Company , Aura Biosciences Inc , Oncology Division , Company Global Phase , Aura Biosciences , Elisabet De Los Pinos , Chief Executive Officer , Compass Phase , Fast Track Designation , Gross Proceeds , Chief Medical Officer , Senior Vice President , Global Head , Exploratory Development , Gyroscope Therapeutics , Chief Technology , Chief Technology Officer , Fate Therapeutics ,

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & DevelopmentMark Plavsic, Ph.D., Appointed as Chief Technology OfficerBOSTON (BUSINESS WIRE) Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC). ....

United Kingdom , United States , Serbia General , Los Pinos , J Jill Hopkins , Mark Plavsic , Jill Hopkins , Sanofi Genzyme , Royal College Of Surgeons Canada , Aura Biosciences Inc , University Of Toronto , Mcmaster University , Technology Development Manufacturing , Technology Officer , University Of Southern California , Research Development , Exploratory Development At Novartis , Vitreous Associates Medical Group , American College Of Veterinary Microbiologists , Regulatory Affairs Certification , University Of Belgrade , Global Head Ophthalmology Personalized Health Care , Company As Senior Clinical Advisor , Exchange Commission , Chief Medical Officer , Chief Technology ,

Aura Biosciences Names Hopkins as Chief Medical Officer

By Oyin Adedoyin Aura Biosciences has appointed Dr. Jill Hopkins as chief medical officer and president of research and development. Mark Plavsic has also. ....

Sanofi Genzyme , Oyin Adeoyin , Mark Plavsic , Jill Hopkins , Oyin Adedoyin , Fate Therapeutics , Cadmus Rich , Article Normal , Biotechnology Services , Healthcare Life Sciences , Biological Therapy , Healthcare Provision , Management Moves , Corporate Industrial News , Senior Level Management , Content Types , Factiva Filters , C Amp Ampe Executive News Filter , C Amp Ampe Industry News Filter , Aura Biosciences , Industrial News , Life Sciences ,